RC-1291
Phase 2Small molecule
RC-1291 is one of 48 small molecule programs targeting Anorexia. It is currently in Phase 2.
2
Indications
3
Total Trials
0
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
105 competitors in Weight Loss
#DrugCompanyPhaseTrials
1Megace
Bristol-Myers SquibbPhase 3
Byetta
AstraZenecaPhase 3
Mounjaro
Eli LillyPhase 3
Revia
TevaPhase 3
Glucophage
EMD SeronoPhase 3
Meridia
AAbbott
Phase 3
Botox
RRevance Therapeutics, Inc.
Phase 3
Cagrilintide
Novo NordiskPhase 3
Rimonabant
SanofiPhase 3
Byetta
Bristol-Myers SquibbPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RC-1291. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- HHelsinn Therapeutics (U.S.), Inc